340B Covered Entity Report
Tags: #Report
... Ozempic. Novo Nordisk. Diabetes. No. No. $6,222,635. 0.41%. OnabotulinumtoxinA Botox. Allergan. Muscle spasticity Yes. Yes. $4,629,817. 0.31%.
Tips:
If the preview is unavailable, open the Source PDF directly from the publisher's website.
Preview availability depends on the publisher's settings, and some documents may restrict third-party iframe preview.
Related PDFs